Skip to main content

Advertisement

SpringerLink
Log in

Colorectal Cancer Screening in Inflammatory Bowel Disease

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Patients with long-standing ulcerative colitis (UC) or Crohn’s colitis are at increased risk of developing colorectal cancer (CRC). Given that most cases of CRC are thought to arise from dysplasia, previous guidelines have recommended endoscopic surveillance with random biopsies obtained from all segments of the colon involved by endoscopic or microscopic inflammation. However, recent evidence has suggested that the majority of dysplastic lesions in patients with inflammatory disease (IBD) are visible, and data have been supportive of chromoendoscopy with targeted biopsies of visible lesions versus traditional random biopsies. This review article will discuss the risk of colon cancer in patients with IBD, as well as current recommendations for CRC screening and surveillance in patients with UC or Crohn’s colitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–774.

    Article  PubMed  Google Scholar 

  2. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–745.

    Article  PubMed  Google Scholar 

  3. Itzkowitz SH, Present DH, Crohn’s, Colitis Foundation of America Colon Cancer in IBDSG. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–321.

    Article  PubMed  Google Scholar 

  4. Leighton JA, Shen B, Baron TH, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006;63:558–565.

    Article  PubMed  Google Scholar 

  5. Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103:2342–2349.

    Article  PubMed  Google Scholar 

  6. Gunther U, Kusch D, Heller F, et al. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. Int J Colorectal Dis. 2011;26:667–672.

    Article  PubMed  Google Scholar 

  7. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148:639–651 e28.

    Article  PubMed  Google Scholar 

  8. Rosenqvist H, Ohrling H, Lagercrantz R, Edling N. Ulcerative colitis and carcinoma coli. Lancet. 1959;1:906–908.

    Article  CAS  PubMed  Google Scholar 

  9. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724–2729.

    Article  PubMed  Google Scholar 

  10. Friedman S, Rubin PH, Bodian C, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn’s colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol. 2008;6:993–998. (quiz 53-4).

    Article  PubMed  Google Scholar 

  11. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35:1590–1592.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375–381 e1. quiz e13-4.

    Article  PubMed  Google Scholar 

  14. Manninen P, Karvonen AL, Huhtala H, et al. The risk of colorectal cancer in patients with inflammatory bowel diseases in Finland: a follow-up of 20 years. J Crohn’s Colitis. 2013;7:e551–e557.

    Article  Google Scholar 

  15. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19:789–799.

    Article  PubMed  Google Scholar 

  16. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345–1353.

    Article  CAS  PubMed  Google Scholar 

  17. Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol. 2011;106:319–328.

    Article  PubMed  Google Scholar 

  18. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut. 2012;61:235–240.

    Article  PubMed  Google Scholar 

  19. Loftus EV Jr. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am. 2006;35:517–531.

    Article  PubMed  Google Scholar 

  20. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–1233.

    Article  CAS  PubMed  Google Scholar 

  21. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clinical Gastroenterol Hepatol. 2012;10:639–645.

    Article  Google Scholar 

  22. Baars JE, Kuipers EJ, van Haastert M, Nicolai JJ, Poen AC, van der Woude CJ. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol. 2012;47:1308–1322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441–1452.

    Article  CAS  PubMed  Google Scholar 

  24. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166–175 e8.

    Article  PubMed  Google Scholar 

  25. Greenstein A, Sachar D, Smith H, et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology. 1979;77:290–294.

    CAS  PubMed  Google Scholar 

  26. Gyde S, Prior P, Allan R, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 1988;29:206–217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561–1567. (quiz 818-9).

    Article  PubMed  Google Scholar 

  28. Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut. 2008;57:1246–1251.

    Article  CAS  PubMed  Google Scholar 

  29. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030–1038.

    Article  PubMed  Google Scholar 

  30. Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356–1362.

    Article  CAS  PubMed  Google Scholar 

  31. Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology. 1998;115:1079–1083.

    Article  CAS  PubMed  Google Scholar 

  32. Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:497–508.

    Article  CAS  PubMed  Google Scholar 

  33. Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22:1404–1408.

    PubMed  Google Scholar 

  34. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48–54.

    Article  PubMed  Google Scholar 

  35. Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation. 2003;75:1983–1988.

    Article  PubMed  Google Scholar 

  36. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099–1105. (quiz 340-1).

    Article  PubMed  PubMed Central  Google Scholar 

  37. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459.

    Article  PubMed  Google Scholar 

  38. Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013;11:1601–1608 e1–4.

    Article  PubMed  Google Scholar 

  39. Lashner BA, Turner BC, Bostwick DG, Frank PH, Hanauer SB. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci. 1990;35:349–352.

    Article  CAS  PubMed  Google Scholar 

  40. Gumaste V, Sachar D, Greenstein A. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992;33:938–941.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lutgens M, Vermeire S, Van Oijen M, et al. A rule for determining risk of colorectal cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:148–154 e1.

    Article  PubMed  Google Scholar 

  42. Rutter M, Saunders B, Wilkinson K, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–1816.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931–968.

    Article  CAS  PubMed  Google Scholar 

  44. Rubin DT, Turner JR. Surveillance of dysplasia in inflammatory bowel disease: the gastroenterologist–pathologist partnership. Clin Gastroenterol Hepatol. 2006;4:1309–1313.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634–1648.

    Article  PubMed  Google Scholar 

  46. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–523. (quiz 24).

    Article  PubMed  Google Scholar 

  47. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohn’s Colitis. 2013;7:1–33.

    Article  Google Scholar 

  48. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666–689.

    Article  PubMed  Google Scholar 

  49. Nugent FW, Haggitt RC, Gilpin P. Cancer surveillance in ulcerative colitis. Gastroenterology. 1991;100:1241–1248.

    CAS  PubMed  Google Scholar 

  50. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000;14:145–153.

    Article  CAS  PubMed  Google Scholar 

  51. Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut. 1998;42:711–714.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lutgens MW, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer. 2009;101:1671–1675.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Löfberg R, Broström O, Karlén P, Tribukait B, Ost A. Colonoscopic surveillance in long-standing total ulcerative colitis—a 15-year follow-up study. Gastroenterology. 1990;99:1021–1031.

    PubMed  Google Scholar 

  54. Ananthakrishnan AN, Cagan A, Cai T, et al. Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2015;13:322–329 e1.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohn’s Colitis. 2013;7:982–1018.

    Article  Google Scholar 

  56. Centre for Clinical Practice at NICE (UK). Colonoscopic Surveillance for Prevention of Colorectal Cancer in People with Ulcerative Colitis, Crohn's Disease or Adenomas. London: National Institute for Health and Clinical Excellence (UK); 2011. (NICE Clinical Guidelines, No. 118). Available from http://www.ncbi.nlm.nih.gov/books/NBK82209/. Accessed 1 Apr 2015.

  57. Committee ASoP, Shergill AK, Lightdale JR, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81:1101–1121 e13.

    Article  Google Scholar 

  58. Blonski W, Kundu R, Lewis J, Aberra F, Osterman M, Lichtenstein GR. Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? Scand J Gastroenterol. 2008;43:698–703.

    Article  PubMed  Google Scholar 

  59. Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65:998–1004.

    Article  PubMed  Google Scholar 

  60. Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60:334–339.

    Article  PubMed  Google Scholar 

  61. van den Broek FJ, Stokkers PC, Reitsma JB, et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol. 2014;109:715–722.

    Article  PubMed  Google Scholar 

  62. Soetikno R, Subramanian V, Kaltenbach T, et al. The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology. 2013;144:1349–1352. 52 e1-6.

    Article  PubMed  Google Scholar 

  63. Picco MF, Pasha S, Leighton JA, et al. Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. Inflamm Bowel Dis. 2013;19:1913–1920.

    PubMed  Google Scholar 

  64. Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am J Gastroenterol. 2015;110:1014–1021.

  65. Konijeti GG, Shrime MG, Ananthakrishnan AN, Chan AT. Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointest Endosc. 2014;79:455–465.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Shergill AK, Farraye FA. Toward a consensus on endoscopic surveillance of patients with colonic inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014;24:469–481.

    Article  PubMed  Google Scholar 

  67. Blackstone MO, Riddell RH, Rogers B, Levin B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology. 1981;80:366–374.

    CAS  PubMed  Google Scholar 

  68. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–857.

    Article  PubMed  Google Scholar 

  69. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58:S3–S43.

  70. Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999;117:1288–1294. (discussion 488-91).

    Article  CAS  PubMed  Google Scholar 

  71. Odze RD, Farraye FA, Hecht JL, Hornick JL. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol. 2004;2:534–541.

    Article  PubMed  Google Scholar 

  72. Vieth M, Behrens H, Stolte M. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut. 2006;55:1151–1155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Moss A, Bourke MJ, Williams SJ, et al. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology. 2011;140:1909–1918.

    Article  PubMed  Google Scholar 

  74. Odze RD, Goldblum J, Noffsinger A, Alsaigh N, Rybicki LA, Fogt F. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol. 2002;15:379–386.

    Article  PubMed  Google Scholar 

  75. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007;25:657–668.

    Article  CAS  PubMed  Google Scholar 

  76. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994;107:934–944.

    CAS  PubMed  Google Scholar 

  77. Hata K, Watanabe T, Kazama S, et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer. 2003;89:1232–1236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125:1311–1319.

    Article  PubMed  Google Scholar 

  79. Navaneethan U, Jegadeesan R, Gutierrez NG, et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J Crohn’s Colitis. 2013;7:e684–e691.

    Article  Google Scholar 

  80. Borjesson L, Willen R, Haboubi N, Duff SE, Hulten L. The risk of dysplasia and cancer in the ileal pouch mucosa after restorative proctocolectomy for ulcerative proctocolitis is low: a long-term term follow-up study. Colorectal Dis. 2004;6:494–498.

    Article  CAS  PubMed  Google Scholar 

  81. Liu ZX, Kiran RP, Bennett AE, Ni RZ, Shen B. Diagnosis and management of dysplasia and cancer of the ileal pouch in patients with underlying inflammatory bowel disease. Cancer. 2011;117:3081–3092.

    Article  PubMed  Google Scholar 

  82. Derikx LA, Kievit W, Drenth JP, et al. Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease. Gastroenterology. 2014;146:119–128 e1.

    Article  PubMed  Google Scholar 

  83. Nguyen GC, Gulamhusein A, Bernstein CN. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol. 2012;107:1298–1304. (quiz 7, 305).

    Article  CAS  PubMed  Google Scholar 

  84. Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12:1793–1800 e1.

    Article  CAS  PubMed  Google Scholar 

  85. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889–893.

    Article  CAS  PubMed  Google Scholar 

  86. Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology. 2008;134:1224–1237.

    Article  CAS  PubMed  Google Scholar 

Download references

Author contribution

Feuerstein and Sengupta studied and designed the concept; Feuerstein, Sengupta, and Yee contributed to the literature review; Sengupta, Feuerstein, and Yee wrote and critically revised the manuscript.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Beth Israel Deaconess Medical Center, 110 Francis St 8E Gastroenterology, Boston, MA, 02215, USA

    Neil Sengupta & Joseph D. Feuerstein

  2. Division of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Eric Yee

Authors
  1. Neil Sengupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Yee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph D. Feuerstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph D. Feuerstein.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sengupta, N., Yee, E. & Feuerstein, J.D. Colorectal Cancer Screening in Inflammatory Bowel Disease. Dig Dis Sci 61, 980–989 (2016). https://doi.org/10.1007/s10620-015-3979-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3979-z

Keywords

Search

Navigation